secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001193125-23-284303
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora receives FDA IND clearance for NMRA-266; starts Phase 1
---------------------------------------------------------------

- NMRA-266 is a positive allosteric modulator of M4 muscarinic receptor, licensed from Vanderbilt University.
- Phase 1 SAD/MAD study initiated in healthy adults after FDA IND clearance on Nov 27, 2023.
- First clinical trial for NMRA-266; aims to evaluate safety, tolerability, and pharmacokinetics.
- Neumora focuses on neuroscience; NMRA-266 could treat schizophrenia and other CNS disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312523284303/0001193125-23-284303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312523284303/d614921d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-284303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer